Background: Cyclosporine is a validated treatment for moderate to severe psoriasis. Long-term cyclosporine administration may induce toxic effects. The duration of treatment usually ranges from 10 to 16 weeks. However, some patients may take cyclosporine for a longer time. Aim: The objective of the present study is to evaluate the dose, efficacy and safety in long-term cyclosporine therapy. Patients and methods: We studied the hospital records of patients with psoriasis treated with cyclosporine between 1 January 2009, and 30 April 2015. We decided to focus on patients who, for different reasons, have continued cyclosporine for more than 2 years. Results: Five patients (2.69%) had been assuming cyclosporine for up to 62 months and had achieved a substantial response with no toxic effects. All of them were concerned about recurrence and all patients had personal reasons to prefer Cyclosporine over other drugs, including: familiar history of neurodegenerative disease, desire for motherhood, easy availability on prescription, systemic scleroderma, belenophobia. Conclusion: Cyclosporine is an acceptable monotherapy for psoriasis in selected patients. The prompt discontinuation of treatment usually results in resolution of any eventual toxicity.

Bardazzi, F., Magnano, M., Balestri, R., Patrizi, A., Tengattini, V. (2016). Focus on five patients treated with cyclosporine up to 62 months. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 27(5), 427-429 [10.3109/09546634.2015.1137273].

Focus on five patients treated with cyclosporine up to 62 months

BARDAZZI, FEDERICO;MAGNANO, MICHELA;BALESTRI, RICCARDO;PATRIZI, ANNALISA;TENGATTINI, VERA
2016

Abstract

Background: Cyclosporine is a validated treatment for moderate to severe psoriasis. Long-term cyclosporine administration may induce toxic effects. The duration of treatment usually ranges from 10 to 16 weeks. However, some patients may take cyclosporine for a longer time. Aim: The objective of the present study is to evaluate the dose, efficacy and safety in long-term cyclosporine therapy. Patients and methods: We studied the hospital records of patients with psoriasis treated with cyclosporine between 1 January 2009, and 30 April 2015. We decided to focus on patients who, for different reasons, have continued cyclosporine for more than 2 years. Results: Five patients (2.69%) had been assuming cyclosporine for up to 62 months and had achieved a substantial response with no toxic effects. All of them were concerned about recurrence and all patients had personal reasons to prefer Cyclosporine over other drugs, including: familiar history of neurodegenerative disease, desire for motherhood, easy availability on prescription, systemic scleroderma, belenophobia. Conclusion: Cyclosporine is an acceptable monotherapy for psoriasis in selected patients. The prompt discontinuation of treatment usually results in resolution of any eventual toxicity.
2016
Bardazzi, F., Magnano, M., Balestri, R., Patrizi, A., Tengattini, V. (2016). Focus on five patients treated with cyclosporine up to 62 months. THE JOURNAL OF DERMATOLOGICAL TREATMENT, 27(5), 427-429 [10.3109/09546634.2015.1137273].
Bardazzi, Federico; Magnano, Michela; Balestri, Riccardo; Patrizi, Annalisa; Tengattini, Vera
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/561672
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact